Mizuho Securities analyst Salim Syed has maintained their bullish stance on BIIB stock, giving a Buy rating on September 24. Salim Syed has ...

Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer's disease therapy lecanemab, which is now fully filed with the FDA.

Biogen has given up on seeking approval for its Alzheimer's disease therapy Aduhelm in the EU, saying that discussions with EU regulators had made it clear the current data for the drug is not ...

WNBA Draft Women's National Basketball Association September 25, 2024 WNBA Draft Women's National Basketball Association September 25, 2024 ...

To sign up for Becker's Payer Issues E-Newsletter or any of our other E-Newsletters, click here. If you are experiencing difficulty receiving our newsletters, you may ...